Roche antibody tops Rituxan in blood cancer CLL PMLiVE Roche said updated results from a phase III study of obinutuzumab (formerly GA101) showed the anti-CD20 antibody improved progression-free survival (PFS) in people with CLL compared to its established product MabThera/ Rituxan (rituximab) when both ... Obinutuzumab Delays Disease Progression in CLL Genentech Trumpets Phase III Results for CLL Candidate |
